Lucira Health, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022025095 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.77M $117.3M
YoY Change -66.09% 71.72%
Cash & Equivalents $39.80M $119.6M
Short-Term Investments
Other Short-Term Assets $3.350M $10.08M
YoY Change -66.77% 48.24%
Inventory $55.63M $42.96M
Prepaid Expenses $2.506M
Receivables $14.39M $11.90M
Other Receivables $4.824M $9.608M
Total Short-Term Assets $120.5M $192.9M
YoY Change -37.54% 156.47%
LONG-TERM ASSETS
Property, Plant & Equipment $48.30M $26.96M
YoY Change 79.17% 308.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $772.0K $245.0K
YoY Change 215.1% -59.17%
Total Long-Term Assets $68.71M $29.93M
YoY Change 129.61% 315.64%
TOTAL ASSETS
Total Short-Term Assets $120.5M $192.9M
Total Long-Term Assets $68.71M $29.93M
Total Assets $189.2M $222.8M
YoY Change -15.08% 170.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $25.17M $10.45M
YoY Change 140.82% 143.09%
Accrued Expenses $55.03M $15.19M
YoY Change 262.2% 659.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $82.52M $27.44M
YoY Change 200.78% 335.49%
LONG-TERM LIABILITIES
Long-Term Debt $29.41M $0.00
YoY Change
Other Long-Term Liabilities $16.37M $1.364M
YoY Change 1099.93% 172.8%
Total Long-Term Liabilities $29.41M $1.364M
YoY Change 2056.01% 172.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $82.52M $27.44M
Total Long-Term Liabilities $29.41M $1.364M
Total Liabilities $128.3M $28.80M
YoY Change 345.47% 323.53%
SHAREHOLDERS EQUITY
Retained Earnings -$264.0M -$120.7M
YoY Change 118.72%
Common Stock $40.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $60.89M $194.0M
YoY Change
Total Liabilities & Shareholders Equity $189.2M $222.8M
YoY Change -15.08% 170.37%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264002000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128541000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
60889000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
188803000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001652724
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39976
dei Entity Registrant Name
EntityRegistrantName
Lucira Health, Inc.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-2491037
dei Entity Address Address Line1
EntityAddressAddressLine1
1412 62nd Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
350-8071
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
LHDX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40598954
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39774000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105982000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14392000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27245000
CY2022Q3 us-gaap Inventory Net
InventoryNet
55625000
CY2021Q4 us-gaap Inventory Net
InventoryNet
50776000
CY2022Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4824000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
8188000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2506000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10274000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3350000
lhdx Noncash Lease Expense
NoncashLeaseExpense
864000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3817000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
120471000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
206282000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48295000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30974000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17704000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2714000
CY2022Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
1943000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
772000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
384000
CY2022Q3 us-gaap Assets
Assets
189185000
CY2021Q4 us-gaap Assets
Assets
240354000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
25173000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
19371000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
55032000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29162000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2316000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1609000
CY2021Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
189000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
82521000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
50331000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29408000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16367000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1220000
CY2022Q3 us-gaap Liabilities
Liabilities
128296000
CY2021Q4 us-gaap Liabilities
Liabilities
51551000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40448703
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40448703
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39663645
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39663645
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
40000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
40000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
324851000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
317304000
CY2021Q3 us-gaap Gross Profit
GrossProfit
-1483000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189185000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
240354000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34390000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14976000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
151010000
us-gaap Gross Profit
GrossProfit
-51647000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31931000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
133945000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14837000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
202657000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32710000
CY2021Q3 lhdx Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
1622000
lhdx Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
1622000
CY2022Q3 us-gaap Gross Profit
GrossProfit
-99555000
us-gaap Gross Profit
GrossProfit
-2401000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9141000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14342000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32089000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30741000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17596000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11788000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
50133000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
23988000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
26737000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
26130000
us-gaap Operating Expenses
OperatingExpenses
82222000
us-gaap Operating Expenses
OperatingExpenses
54729000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-126292000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-27613000
us-gaap Operating Income Loss
OperatingIncomeLoss
-133869000
us-gaap Operating Income Loss
OperatingIncomeLoss
-57130000
CY2022Q3 lhdx Investment Income And Other Nonoperating Income Expense
InvestmentIncomeAndOtherNonoperatingIncomeExpense
393000
CY2021Q3 lhdx Investment Income And Other Nonoperating Income Expense
InvestmentIncomeAndOtherNonoperatingIncomeExpense
117000
lhdx Investment Income And Other Nonoperating Income Expense
InvestmentIncomeAndOtherNonoperatingIncomeExpense
736000
lhdx Investment Income And Other Nonoperating Income Expense
InvestmentIncomeAndOtherNonoperatingIncomeExpense
399000
CY2022Q3 us-gaap Interest Expense
InterestExpense
949000
us-gaap Interest Expense
InterestExpense
2312000
us-gaap Interest Expense
InterestExpense
281000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-556000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
117000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1576000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
118000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-126848000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27496000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-135445000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57012000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-126862000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-27496000
us-gaap Net Income Loss
NetIncomeLoss
-135461000
us-gaap Net Income Loss
NetIncomeLoss
-57012000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.15
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.15
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.71
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40216244
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
154000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
519000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
324000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
332000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5028000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-27496000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
193988000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
188803000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
494000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40216244
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38667615
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38667615
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39974997
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39974997
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33348104
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33348104
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
185067000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
220000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2431000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-126862000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
60889000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
215800000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6380000
us-gaap Net Income Loss
NetIncomeLoss
-135461000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
60889000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-62308000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
121080000
lhdx Stock Issued During Period Value Convertible Notes In To Common Stock
StockIssuedDuringPeriodValueConvertibleNotesInToCommonStock
24982000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
159898000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
516000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
332000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6500000
us-gaap Net Income Loss
NetIncomeLoss
-57012000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
193988000
us-gaap Profit Loss
ProfitLoss
-135461000
us-gaap Profit Loss
ProfitLoss
-57012000
us-gaap Share Based Compensation
ShareBasedCompensation
5796000
us-gaap Share Based Compensation
ShareBasedCompensation
6500000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-67000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
259000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5015000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2158000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1622000
lhdx Charge For Excess Inventory And Non Cancellable Purchase Commitments
ChargeForExcessInventoryAndNonCancellablePurchaseCommitments
107159000
lhdx Charge For Excess Inventory And Non Cancellable Purchase Commitments
ChargeForExcessInventoryAndNonCancellablePurchaseCommitments
1284000
lhdx Accretion And Amortization Of Term Loans Discount
AccretionAndAmortizationOfTermLoansDiscount
503000
lhdx Remeasurement Of Derivative Liabilities And Convertible Notes
RemeasurementOfDerivativeLiabilitiesAndConvertibleNotes
281000
us-gaap Paid In Kind Interest
PaidInKindInterest
3000
lhdx Noncash Lease Expense
NoncashLeaseExpense
-1000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
74100000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
39383000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-12920000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11870000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-3364000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-58000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-885000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4669000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-181000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
7165000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4051000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6472000
lhdx Increase Decrease In Contract With Customer Refund Liability
IncreaseDecreaseInContractWithCustomerRefundLiability
-189000
lhdx Increase Decrease In Contract With Customer Refund Liability
IncreaseDecreaseInContractWithCustomerRefundLiability
365000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3236000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10255000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-72315000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90843000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21401000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10777000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21401000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10777000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
29570000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
740000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
159898000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
102000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
464000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
519000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
332000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29451000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
160694000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-64265000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
59074000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
105982000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60550000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41717000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
119624000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39774000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117286000
CY2022Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
1943000
CY2021Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
2338000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41717000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
119624000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
16000
us-gaap Interest Paid Net
InterestPaidNet
1529000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2220000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
550000
CY2022Q3 us-gaap Revenues
Revenues
34400000
us-gaap Revenues
Revenues
151000000.0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
16443000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2362000
lhdx Issuance Of Warrants In Connection With Term Loan
IssuanceOfWarrantsInConnectionWithTermLoan
494000
lhdx Vesting Of Early Exercise Options
VestingOfEarlyExerciseOptions
52000
lhdx Vesting Of Early Exercise Options
VestingOfEarlyExerciseOptions
52000
lhdx Stock Based Compensation Expense Adjustments To Inventory
StockBasedCompensationExpenseAdjustmentsToInventory
584000
lhdx Stock Based Compensation Expense Adjustments To Inventory
StockBasedCompensationExpenseAdjustmentsToInventory
360000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
24982000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
121080000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2013-02-20
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-126900000
us-gaap Net Income Loss
NetIncomeLoss
-135500000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-27500000
us-gaap Net Income Loss
NetIncomeLoss
-57000000.0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
13100000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39800000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264000000.0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:5.2%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the conflicts in Ukraine and potential resurgence related to the COVID-19 pandemic and actions taken to slow its spread, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. If the Company is not able to secure adequate additional funding when needed, the Company will need to re-evaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, limit, suspend or curtail planned test kit development programs and commercialization efforts, and cease operations entirely. Having insufficient funds may also require the Company to relinquish rights to technology that it would otherwise prefer to develop and market itself, or on less favorable terms than the Company would otherwise choose. The foregoing actions and circumstances could materially adversely impact the Company's business, results of operations and future prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.2%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to recognition of stock-based compensation, incremental borrowing rate,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">revenue recognition, inventory valuation,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales returns, warranty reserves, allowance for doubtful accounts, accrued research and development costs, uncertain tax positions, the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recoverability of its long-lived assets and the valuation of deferred tax assets. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></p>
CY2022Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
1900000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39800000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
106000000.0
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:5.2%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain prior period amounts have been reclassified to conform to the current period presentation. The impact of these reclassifications did not have an impact to the current assets and liabilities, the statements of operations or net operating cash flows.</span></p>
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
options to extend
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2021Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1600000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1600000
lhdx Redeemable Convertible Preferred Stock Redemption Period After Occurrence Of Certain Liquidation Events
RedeemableConvertiblePreferredStockRedemptionPeriodAfterOccurrenceOfCertainLiquidationEvents
P90D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34390000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14976000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
151010000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31931000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34390000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14976000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
151010000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31931000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
133945000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14837000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
202657000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32710000
CY2021Q3 lhdx Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
1622000
lhdx Impairment Of Long Lived Assets
ImpairmentOfLongLivedAssets
1622000
CY2022Q3 us-gaap Gross Profit
GrossProfit
-99555000
CY2021Q3 us-gaap Gross Profit
GrossProfit
-1483000
us-gaap Gross Profit
GrossProfit
-51647000
us-gaap Gross Profit
GrossProfit
-2401000
CY2022Q3 lhdx Percentage Of Gross Margin
PercentageOfGrossMargin
-2.89
CY2021Q3 lhdx Percentage Of Gross Margin
PercentageOfGrossMargin
-0.10
lhdx Percentage Of Gross Margin
PercentageOfGrossMargin
-0.34
lhdx Percentage Of Gross Margin
PercentageOfGrossMargin
-0.08
CY2021Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1600000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1600000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34390000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14976000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
151010000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31931000
CY2022Q3 us-gaap Other Commitment
OtherCommitment
36200000
lhdx Forecast Rolling Period
ForecastRollingPeriod
P12M
lhdx Each Forecast Required Period
EachForecastRequiredPeriod
P4M
CY2022Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
16477000
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
35923000
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
28579000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
10539000
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10569000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4314000
CY2022Q3 us-gaap Inventory Net
InventoryNet
55625000
CY2021Q4 us-gaap Inventory Net
InventoryNet
50776000
CY2022Q3 lhdx Accrued Inventory Related To Excess Non Cancellable Purchase Commitments For Raw Materials
AccruedInventoryRelatedToExcessNonCancellablePurchaseCommitmentsForRawMaterials
30000000.0
CY2022Q3 us-gaap Inventory Raw Materials And Purchased Parts Net Of Reserves
InventoryRawMaterialsAndPurchasedPartsNetOfReserves
3800000
CY2021Q4 us-gaap Inventory Raw Materials And Purchased Parts Net Of Reserves
InventoryRawMaterialsAndPurchasedPartsNetOfReserves
0.0
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
1300000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
400000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
58146000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
35811000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9851000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4837000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48295000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30974000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1700000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5000000.0
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1300000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2200000
us-gaap Property Plant And Equipment Transfers And Changes
PropertyPlantAndEquipmentTransfersAndChanges
1000000.0
CY2021Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1600000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1600000
CY2022Q3 us-gaap Noncurrent Assets
NoncurrentAssets
65999000
CY2021Q4 us-gaap Noncurrent Assets
NoncurrentAssets
33688000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
99000
lhdx Allowance For Doubtful Accounts Receivable Amounts Charged To Costs And Expenses Recoveries
AllowanceForDoubtfulAccountsReceivableAmountsChargedToCostsAndExpensesRecoveries
-133000
CY2021 lhdx Allowance For Doubtful Accounts Receivable Amounts Charged To Costs And Expenses Recoveries
AllowanceForDoubtfulAccountsReceivableAmountsChargedToCostsAndExpensesRecoveries
358000
lhdx Allowance For Doubtful Accounts Receivable Recoveries Write Off
AllowanceForDoubtfulAccountsReceivableRecoveriesWriteOff
153000
CY2021 lhdx Allowance For Doubtful Accounts Receivable Recoveries Write Off
AllowanceForDoubtfulAccountsReceivableRecoveriesWriteOff
259000
lhdx Allowance For Doubtful Accounts Receivable Recovery Of Previous Write Off
AllowanceForDoubtfulAccountsReceivableRecoveryOfPreviousWriteOff
200000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
13000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
99000
CY2022Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4824000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
8188000
CY2022Q3 us-gaap Prepaid Taxes
PrepaidTaxes
871000
CY2021Q4 us-gaap Prepaid Taxes
PrepaidTaxes
307000
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1635000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
588000
CY2021Q4 lhdx Prepaid Inventory
PrepaidInventory
9379000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2506000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10274000
CY2022Q3 lhdx Prepaid Inventories Current
PrepaidInventoriesCurrent
0.0
CY2021Q4 lhdx Prepaid Inventories Current
PrepaidInventoriesCurrent
9400000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1423000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
612000
CY2022Q3 lhdx Accrued Manufacturing And Inventory Purchases Current
AccruedManufacturingAndInventoryPurchasesCurrent
16400000
CY2021Q4 lhdx Accrued Manufacturing And Inventory Purchases Current
AccruedManufacturingAndInventoryPurchasesCurrent
17200000
CY2022Q3 lhdx Accrued Non Cancellable Purchase Commitments Current
AccruedNonCancellablePurchaseCommitmentsCurrent
29974000
CY2022Q3 lhdx Accrued Canada Importation Taxes Current
AccruedCanadaImportationTaxesCurrent
2376000
CY2021Q4 lhdx Accrued Canada Importation Taxes Current
AccruedCanadaImportationTaxesCurrent
1551000
CY2022Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
2098000
CY2021Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
4466000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1662000
CY2022Q3 lhdx Accrued Sales Taxes Current
AccruedSalesTaxesCurrent
1496000
CY2021Q4 lhdx Accrued Sales Taxes Current
AccruedSalesTaxesCurrent
2215000
CY2022Q3 lhdx Accrued Early Exercise Liability Current
AccruedEarlyExerciseLiabilityCurrent
138000
CY2021Q4 lhdx Accrued Early Exercise Liability Current
AccruedEarlyExerciseLiabilityCurrent
189000
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
281000
CY2022Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
421000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
425000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1267000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
55032000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
29162000
CY2022Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1200000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8100000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
8100000
CY2022Q2 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
700000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8600000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
8600000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
434000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2726000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2922000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2899000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2994000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
17010000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
28985000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10302000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
18683000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2316000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16367000
us-gaap Operating Lease Payments
OperatingLeasePayments
1400000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1126000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
253000
us-gaap Operating Lease Cost
OperatingLeaseCost
2450000
us-gaap Operating Lease Cost
OperatingLeaseCost
471000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
467000
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
312000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
790000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
939000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y9M21D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M25D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0949
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0715
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 lhdx Lessor Facility Leases Amendment Description
LessorFacilityLeasesAmendmentDescription
In addition to the Vista and Berkley California leases, the Company has executed certain amendments to lease facilities in Emeryville and San Jose California. These amendments are the result of the Company's consolidation of certain of its locations and departments. Upon the execution of each of the amendments, which were deemed to be lease modifications, the Company remeasured the respective lease liabilities and corresponding ROU assets as of the effective date of each amendment and recorded a net reduction of $0.1 million during the nine months ended September 30, 2022 of the lease liabilities and respective ROU assets.
lhdx Facility Lease Reduction Of Lease Liabilities
FacilityLeaseReductionOfLeaseLiabilities
100000
lhdx Facility Lease Reduction Of Right Of Use Assets
FacilityLeaseReductionOfRightOfUseAssets
100000
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
31575000
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2167000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29408000
CY2022Q3 lhdx Contractual Coupon
ContractualCoupon
832000
lhdx Contractual Coupon
ContractualCoupon
1959000
CY2022Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
195000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
502000
CY2022Q3 lhdx Interest Expense Debt Excluding Other Interest Expense
InterestExpenseDebtExcludingOtherInterestExpense
1027000
lhdx Interest Expense Debt Excluding Other Interest Expense
InterestExpenseDebtExcludingOtherInterestExpense
2461000
CY2022Q3 us-gaap Interest Expense Other
InterestExpenseOther
12000
us-gaap Interest Expense Other
InterestExpenseOther
50000
CY2022Q3 us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
90000
us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
199000
CY2022Q3 us-gaap Interest Expense
InterestExpense
949000
us-gaap Interest Expense
InterestExpense
2312000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Under the Loan Agreement, as amended, the Company is precluded from declaring or paying cash dividends, subject to certain exceptions. The holder of each share of common stock is entitled to one vote.
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14602228
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9388184
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2372000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5028000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5796000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6500000
CY2022Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
400000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
1300000
CY2021Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
100000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
400000
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
2431000
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
5028000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
6380000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
6500000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
24700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3712274
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.30
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23150000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
431213
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.88
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
73940
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
343954
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.05
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3725593
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
337947000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3725593
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
337947000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2154038
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
2.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
288503000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
842371
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14000.0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16000.0
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1100000
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-126862000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-27496000
us-gaap Net Income Loss
NetIncomeLoss
-135461000
us-gaap Net Income Loss
NetIncomeLoss
-57012000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40216244
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40216244
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38667615
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38667615
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39974997
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39974997
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33348104
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33348104
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.15
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.15
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.71
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8146717
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6476473
CY2022Q3 lhdx Related Party Transaction Consulting Expenses
RelatedPartyTransactionConsultingExpenses
100000
lhdx Related Party Transaction Consulting Expenses
RelatedPartyTransactionConsultingExpenses
100000
CY2021Q3 lhdx Related Party Transaction Consulting Expenses
RelatedPartyTransactionConsultingExpenses
100000
lhdx Related Party Transaction Consulting Expenses
RelatedPartyTransactionConsultingExpenses
100000

Files In Submission

Name View Source Status
0000950170-22-025095-index-headers.html Edgar Link pending
0000950170-22-025095-index.html Edgar Link pending
0000950170-22-025095.txt Edgar Link pending
0000950170-22-025095-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img9040916_0.jpg Edgar Link pending
img9040916_1.jpg Edgar Link pending
img9040916_2.jpg Edgar Link pending
img9040916_3.jpg Edgar Link pending
lhdx-20220930.htm Edgar Link pending
lhdx-20220930.xsd Edgar Link pending
lhdx-ex10_1.htm Edgar Link pending
lhdx-ex31_1.htm Edgar Link pending
lhdx-ex31_2.htm Edgar Link pending
lhdx-ex32_1.htm Edgar Link pending
lhdx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
lhdx-20220930_pre.xml Edgar Link unprocessable
lhdx-20220930_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
lhdx-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
lhdx-20220930_def.xml Edgar Link unprocessable
lhdx-20220930_cal.xml Edgar Link unprocessable